Deals
Astorg Nears $2.6 Billion Acquisition of CordenPharma
- CordenPharma’s founders will reinvest alongside Astorg
- Astorg beat out rival private equity firms for CordenPharma
This article is for subscribers only.
Astorg Partners will acquire contract drug development and manufacturing company CordenPharma, in one of the year’s largest private equity deals in European health care.
The French private equity firm is buying the business from International Chemical Investors Group, according to a statement Monday that confirmed an earlier Bloomberg News report. Under the terms of the deal, CordenPharma’s founders will reinvest as partners with Astorg.